Replimune Group, Inc. 8-K

What Happened
Replimune Group, Inc. announced that on April 10, 2026 it received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The company furnished a news release about the CRL and reported the matter on Form 8-K filed April 13, 2026.

Key Details

• Date received: April 10, 2026; Form 8-K filed April 13, 2026.
• Product and indication: RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.
• Regulatory action: Second Complete Response Letter from the FDA (company did not disclose the CRL’s specific contents in the filing).
• Company disclosed the news release as Exhibit 99.1 to the Form 8-K.

Why It Matters
A CRL means the FDA has identified issues that prevent approval of the BLA as submitted; a second CRL can delay potential approval and commercial timelines for RP1 if the company must address additional data, manufacturing, or other deficiencies. The filing does not describe the FDA’s specific concerns or Replimune’s next steps, so investors should watch for follow-up disclosures on the company’s planned response, resubmission timeline, or any impact on financial outlook and development plans.